SKA1 (spindle and kinetochore associated complex subunit 1) is a component of the SKA complex, a microtubule plus end-binding complex at the outer kinetochore that stabilizes spindle microtubule-kinetochore attachments and promotes chromosome 18 123. Within the kinetochore architecture, SKA1 mediates interactions with dynamic microtubules, facilitating end-on attachment of the NDC80 complex to depolymerizing spindle microtubules 345. The SKA complex recruits protein phosphatase 1 (PP1) to suppress spindle assembly checkpoint signaling and promote anaphase onset 6. Clinically, SKA1 displays dysregulation across multiple cancer types with significant prognostic implications. Pan-cancer analysis reveals SKA1 upregulation associated with poor clinical outcomes 789. Functional studies demonstrate that SKA1 knockdown inhibits cell proliferation, migration, and cell cycle progression in adenoid cystic carcinoma, bladder cancer, and esophageal carcinoma 10118. In osteosarcoma, hypoxia-mediated SKA1 downregulation increases chemotherapy resistance, suggesting SKA1 levels modulate chemosensitivity 12. Mechanistically, SKA1 promotes cancer progression through multiple pathways including AKT-FOXO3a signaling in ovarian cancer 7 and P53 signaling in laryngocarcinoma 13. These findings position SKA1 as both a prognostic biomarker and potential therapeutic target across multiple malignancies.